Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating amyloid-related diseases

a technology for amyloid fibrils and compositions, applied in the direction of drug compositions, peptides, cardiovascular disorders, etc., can solve the problems of amyloid fibrils, once deposited, becoming toxic to surrounding cells, severe pain, joint stiffness and swelling,

Inactive Publication Date: 2007-01-11
BELLUS HEALTH (INT) LTD (CH)
View PDF82 Cites 56 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024] The present invention relates to the use of certain compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of a compound of the invention. The invention also pertains to each of the novel compounds of the invention as described herein. Among the compounds for use in the invention are those according to the following Formulae, such that, when administered, amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity is reduced or inhibited.
[0092] In one embodiment, the compounds disclosed herein prevent or inhibit amyloid protein assembly into insoluble fibrils which, in vivo, are deposited in various organs, or it favors clearance of pre-formed deposits or slows deposition in patients already having deposits. In another embodiment, the compound may also prevent the amyloid protein, in its soluble, oligomeric form or in its fibrillar form, from binding or adhering to a cell surface and causing cell damage or toxicity. In yet another embodiment, the compound may block amyloid-induced cellular toxicity or macrophage activation. In another embodiment, the compound may block amyloid-induced neurotoxicity or microglial activation. In another embodiment, the compound protects cells from amyloid induced cytotoxicity of B-islet cells. In another embodiment, the compound may enhance clearance from a specific organ, e.g., the brain or it decreases concentration of the amyloid protein in such a way that amyloid fibril formation is prevented in the targeted organ.
[0094] The compounds of the invention may be administered therapeutically or prophylactically to treat diseases associated with amyloid-β fibril formation, aggregation or deposition. The compounds of the invention may act to ameliorate the course of an amyloid-β related disease using any of the following mechanisms (this list is meant to be illustrative and not limiting): slowing the rate of amyloid-β fibril formation or deposition; lessening the degree of amyloid-β deposition; inhibiting, reducing, or preventing amyloid-β fibril formation; inhibiting neurodegeneration or cellular toxicity induced by amyloid-β; inhibiting amyloid-β induced inflammation; enhancing the clearance of amyloid-β from the brain; or favoring the degradation of amyloid-β protein prior to its organization in fibrils.

Problems solved by technology

Once these amyloids have formed, there is no known, widely accepted therapy or treatment which significantly dissolves amyloid deposits in situ, prevents further amyloid deposition or prevents the initiation of amyloid deposition.
In specific cases, amyloid fibrils, once deposited, can become toxic to the surrounding cells.
This causes severe pains, joint stiffness and swelling.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating amyloid-related diseases
  • Methods and compositions for treating amyloid-related diseases
  • Methods and compositions for treating amyloid-related diseases

Examples

Experimental program
Comparison scheme
Effect test

examples

Binding and Antifibrillogenic Assays

[0427] The test compounds were synthesized and screened by mass spectrometry (“MS”) assays, except for selected compounds which were purchased from a commercial source. The MS assay gives data on the ability of compounds to bind to proteins, in this example, to β-amyloid and IAPP.

[0428] In the MS assay for Aβ40, samples were prepared as aqueous solutions (adding 20% ethanol if necessary to solubilize in water), 200 μM of a test compound and 20 μM of solubilized Aβ40, or 400 μM of a test compound and 40 μM of solubilized Aβ40. The pH value of each sample was adjusted to 7.4 (±0.2) by addition of 0. 1% aqueous sodium hydroxide. The solutions were then analyzed by electrospray ionization mass spectrometry using a Waters ZQ 4000 mass spectrometer. Samples were introduced by direct infusion at a flow-rate of 25 μL / min within. 2 hours after sample preparation. The source temperature was kept at 70° C. and the cone voltage was 20 V for all the analysi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
pHaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Description

RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Patent Application 60 / 638,819, filed on Dec. 22, 2004. This application is also a continuation-in-part of U.S. patent appplication Ser. No. 10 / 871,514, filed Jun. 18, 2004, which claims priority to U.S. patent application Ser. No. 10 / 871,365 filed Jun. 18, 2004, U.S. Provisional Patent Application No. 60 / 512,047, filed Oct. 17, 2003, and U.S. Provisional Patent Application No. 60 / 480,906, filed Jun. 23, 2003, all entitled Methods and Compositions for Treating Amyloid-Related Diseases. This application is also related to U.S. Provisional Application Serial No. 60 / 638,636, filed Dec. 22, 2004. [0002] This application is also related to U.S. Provisional Patent Application No. 60 / 512,017, filed Oct. 17, 2003, U.S. Provisional Patent Application No. 60 / 480,918, filed Jun. 23, 2003, and U.S. patent application Ser. No. 10 / 871,613, filed Jun. 18, 2004, all entitled Methods for Treating Protein Aggregation Diso...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/405A61K31/277A61K31/198C07D209/20C07C309/13
CPCC07C307/02C07C309/13C07C309/15C07C309/19C07C309/23C07C309/46C07C309/69C07C311/32C07C311/46C07C323/25C07C323/58C07C335/12C07C335/32C07C381/02C07D209/08C07D209/14C07D209/20C07D209/44C07D209/48C07D211/46C07D211/64C07D211/70C07D217/04C07D217/10C07D235/28C07D257/04C07D295/084C07D295/088C07D317/50C07D401/04C07D403/04C07D403/06C07D453/02C07D471/04C07F9/1651C07F9/2458C07C2601/02C07C2601/04C07C2601/08C07C2601/10C07C2601/14C07C2601/18C07C2602/08C07C2602/10C07C2602/42C07C2603/74C07C309/14C07D209/18A61P17/00A61P25/28A61P9/00C07K5/0812
Inventor KONG, XIANQIMIGNEAULT, DAVIDVALADE, ISABELLEWU, XINFUGERVAIS, FRANCINE
Owner BELLUS HEALTH (INT) LTD (CH)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products